NDAOPHTHALMICEMULSION
Approved
Sep 2018
Lifecycle
Peak
Competitive Pressure
8/100
Clinical Trials
20
Data completeness
6/8 — Strong
XELPROS (latanoprost) by Fosun Pharma is 2α analogue that is believed to reduce the iop by increasing the outflow of aqueous humor. Approved for ocular hypertension, open-angle glaucoma, glaucoma and 1 more indications. First approved in 2018.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XELPROS is a prostaglandin F2α analogue ophthalmic emulsion approved in 2018 for glaucoma and ocular hypertension. It reduces intraocular pressure (IOP) by increasing uveoscleral outflow of aqueous humor, addressing a major risk factor for optic nerve damage and visual field loss. The formulation represents an innovation in drug delivery for a well-established therapeutic class.
$0.004BPart D
Peak3.4 years to LOEXELPROS is in peak commercial phase but faces high competitive pressure (8/10); expect stable to modest team sizing focused on differentiation and market defense.
Mechanism of Action
2α analogue that is believed to reduce the IOP by increasing the outflow of aqueous humor. Studies in animals and man suggest that the main mechanism of action is increased uveoscleral outflow. Elevated IOP represents a major risk factor for glaucomatous field loss. The higher the level of IOP, the…
Pharmacologic Class:
Prostaglandin Analog
Indications (4)
Worked on XELPROS at Fosun Pharma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.